tirzepatide chemical structure molecule Antidiabetic drug molecular structure, illustration - Stock Image RCSB PDB - 7FIM: Cryo-EM

Identify the route and formulation

These agents should be used with caution in immobile patients or those with dysphagia due to the risk of oesophageal or intestinal obstruction if taken with insufficient fluid

Preliminary safety reporting indicated: GI adverse event profile consistent with Phase 2 data No new safety signals identified beyond those observed in earlier trials Discontinuation rates due to adverse events were comparable to other GLP-1 class trials Full adverse event tables from TRIUMPH-4 are expected with the peer-reviewed publication

Use this tool to get the proper dosage for sexual health benefits

Over 18 months, participants were divided into two groups half received the active medication while the other half received placebo treatment